中間リスク前立腺癌の局所アブレーションのための証拠に基づく局所凍結療法プロトコル
To learn if using cryotherapy to treat only the part of the prostate known to contain cancer is effective in controlling prostate cancer
調査の概要
詳細な説明
Primary Objective:
• To determine the effectiveness of an evidence-based focal cryotherapy ablation by measuring negative in-field recurrence rate at 6-months post-ablation.
Secondary Objectives:
- To determine quality of life following focal prostate cancer ablation using validated questionnaires (EPIC-26, AUA symptoms score, SHIM).
- To establish PSA kinetics post-evidence-based focal cryotherapy ablation.
- To determine rates of out of field recurrence on 6-month biopsy following focal cryotherapy ablation.
- To determine MRI findings post-focal cryotherapy ablation, including those related to prostate and surrounding periprostatic fat volume.
- To determine rate of progression and re-intervention collected as part of standard of care treatment for 5-year following study treatment.
- To describe financial toxicity associated with focal prostate cancer treatment using cryotherapy.
- To describe the incidence and severity of complications within 30-days after the study focal ablation treatment.
- To describe imaging findings on PSMA PET MRI performed in a subset of men after standard of care focal cryotherapy prior to 6-month biopsy.
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究連絡先
- 名前:Justin Gregg, MD
- 電話番号:713-792-3250
- メール:jrgregg@mdanderson.org
研究場所
-
-
Texas
-
Houston、Texas、アメリカ、77030
- 募集
- MD Anderson Cancer Center
-
主任研究者:
- Justin Gregg, MD
-
コンタクト:
- Justin Gregg, MD
- 電話番号:(713) 792-3250
- メール:jrgregg@mdanderson.org
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion criteria:
-
English-speaking adult males
-
Life expectancy over 10 years as assessed by treating physician
-
Prior to enrollment, MRI fusion biopsy of MRI-visible lesion required (as detailed below, which includes systematic biopsy cores)
-
Single focus GG2 or GG3 (additional GG1 allowed up to 6mm, noting that a single focus of disease is defined as an area seen on MRI that may be biopsied multiple times using targeted biopsies and have systematic core biopsies directly adjacent to targeted cores; all of which being considered as from the same focus)
- Histologically confirmed adenocarcinoma of prostate
- Organ-confined prostate cancer, clinical stage ≤T2bN0M0
- Visible tumor on MRI
- No clear evidence or high suspicion of extraprostatic extension or seminal vesical invasion on MRI
- Biopsy via transperineal or transrectal approach with at least 2 cores of MRI visible lesions that are PIRADS 2 or higher and 12 core systematic biopsy template (exclusion of cores from systematic template that overlap with targeted cores allowed).
- Additional performance of microultrasound guided biopsy is allowed though not required. Please note that every effort will be made to correlate microultrasound findings with MRI, in order to determine if positive results are from the same MRIvisible focus. This determination will be made by the surgeon performing the biopsy.
- Note that GGG 1 disease at sites other than ablation zone are allowed provided these are 6mm or less in size. PSA ≤15 ng/mL, or PSAD <0.15 if PSA >15 ng/mL
-
Physician can fully visualize the prostate on transrectal ultrasound on entry biopsy
-
Lesion anatomically amenable to cryotherapy treatment based on treating physician's discretion
-
Willing and able to read, understand and sign the study specific informed consent document
-
Willing and agreeable to comply with study protocol requirements, including focal cryotherapy ablation and all follow up visit requirements
-
Patients must consent to investigative laboratory protocol (such as, but not limited to, 2021- 0560)
Exclusion criteria:
- Gleason grade group 4 or 5 disease
- Medical history or concurrent disease, which in the opinion of the investigator, poses the patient at significant peri-operative risk of complication due to anesthesia or the procedure
- Active urinary tract infection
- Any previous treatment for prostate cancer, including radiation therapy, hormonal treatment, biologic therapy for prostate cancer, or chemotherapy
- Prior TURP or other prostate outlet procedure such as HoLEP, greenlight, microwave ablation, aquablation, UroLift, or simple prostatectomy.
- Previous rectal surgery (other than hemorrhoidectomy) or history of rectal disease
- Inability to obtain prostate MRI (ex. due to claustrophobia, pacemaker, or prohibitive implants)
- Unwilling to consent to laboratory investigative protocol (such as, but not limited to, 2021- 0560)
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Focal therapy Treatment
Cryoablation is a procedure in which special needles are inserted into the tumor site. |
Participants will have the Focal cryoablation placed by the needles in such a way that the area of affected tissue is much smaller and focus just on the tumor tissue and surrounding area Participants will receive a prostate biopsy. Participants will fill out questionnaires. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Quality-of-life Questionnaires
時間枠:through completion an average of 1 year.
|
Score scale ranges (0-5) 0-Not at all/5- Almost always |
through completion an average of 1 year.
|
協力者と研究者
捜査官
- 主任研究者:Justin Gregg, MD、jrgregg@mdanderson.org
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 2022-0165
- NCI-2022-05462 (その他の識別子:NCI-CTRP Clinical Trials Reporting Registry)
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。